Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.

Wieduwilt, Matthew J; Metheny, Leland; Zhang, Mei-Jie; Wang, Hai-Lin; Estrada-Merly, Noel; Marks, David I; Al-Homsi, A Samar; Muffly, Lori; Chao, Nelson J; Rizzieri, David; Gale, Robert Peter; Gadalla, Shahinaz M; Cairo, Mitchell S; Mussetti, Alberto; Gore, Steven D; Bhatt, Vijaya Raj; Patel, Sagar S; Michelis, Fotios V; Inamoto, Yoshihiro; Badawy, Sherif M; ... (2022). Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood advances, 6(1), pp. 339-357. American Society of Hematology 10.1182/bloodadvances.2021004916

bloodadvances.2021004916.pdf - Published Version
Available under License Publisher holds Copyright.

Download (1MB) | Preview

The role of haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariate analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) between haploidentical HCT using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD) , 7/8 HLA-matched UD, or umbilical cord blood (UCB) HCT. Comparing haploidentical to MSD HCT, OS, leukemia-free survival (LFS), non-relapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher with MSD HCT. Compared to MUD HCT, OS, LFS, and relapse were not different but MUD HCT had increased NRM (HR 1.42, P=0.02), grade 3-4 aGVHD (HR 1.59, P=0.005), and cGVHD. Compared to 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR 1.38, P=0.01) and increased NRM (HR 2.13, P=<0.001), grade 3-4 aGVHD (HR 1.86, P=0.003), and cGVHD (HR 1.72, P=<0.001). Compared to UCB HCT, late OS , late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months, HR 1.93, P<0.001), worse early LFS (HR 1.40, P=0.007) and increased incidences of NRM (HR 2.08, P<0.001) and grade 3-4 aGVHD (HR 1.97, P<0.001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared to traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in CR.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)

UniBE Contributor:

Bacher, Vera Ulrike


600 Technology > 610 Medicine & health




American Society of Hematology




Pierrette Durand Lüthi

Date Deposited:

11 Oct 2021 15:51

Last Modified:

16 Oct 2023 11:01

Publisher DOI:


PubMed ID:






Actions (login required)

Edit item Edit item
Provide Feedback